康柏西普与雷珠单抗治疗新生血管性青光眼的临床疗效探讨  

Clinical efficacy of conbercept and ranibizumab in the treatment of neovascular glaucoma

作　　者：杨威 YANG Wei(Jinzhou He Eye Specialist Hospital,Dalian 116600,China)

机构地区：[1]大连金州何氏眼科医院,116600

出　　处：《中国实用医药》2022年第10期27-29,共3页China Practical Medicine

摘　　要：目的 探究康柏西普与雷珠单抗治疗新生血管性青光眼的临床疗效。方法 100例新生血管性青光眼患者,随机分为实验组与对照组,各50例。实验组患者采取雷珠单抗注射治疗,对照组患者采取康柏西普注射治疗。比较两组手术成功率、术后2~7 d房角及巩膜NV消退情况、治疗前后眼压变化情况、并发症发生情况。结果 术后2周、1个月、6个月,两组手术成功率比较,差异均无统计学意义(P>0.05)。实验组术后2~7 d房角及巩膜新生血管(NV)完全消退率为94.00%,明显高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗7 d及治疗1个月后,实验组眼压分别为(21.18±4.57)、(22.06±4.61)mm Hg(1 mm Hg=0.133 kPa),均明显低于对照组的(24.06±5.03)、(25.07±5.13)mm Hg,差异有统计学意义(P<0.05);治疗6个月后,两组眼压比较,差异无统计学意义(P>0.05)。两组患者包裹泡形成、引力管堵塞或者移位暴露、虹膜睫状体炎、前房出血、浅前房、低眼压发生率比较,差异均无统计学意义(P>0.05)。结论 在新生血管性青光眼患者中采取雷珠单抗治疗短期治疗效果优于康柏西普,长期治疗效果两种治疗方式差异不明显,且两种治疗方式不良反应都比较少,安全性高,值得临床推广应用。Objective To investigate the clinical efficacy of conbercept and ranibizumab in the treatment of neovascular glaucoma.Methods A total of 100 cases of neovascular glaucoma were randomly divided into experimental group and control group,with 50 cases in each group.Patients in the experimental group were treated with ranibizumab injection,and patients in the control group were treated with conbercept injection.The surgical success rate,regression of angle and scleral NV at 2-7 d postoperatively,intraocular pressure changes before and after treatment,and complications were compared between the two groups.Results At 2 weeks,1 month and 6 months postoperatively,there was no statistically significant in surgical success rate between the two groups(P>0.05).The probability of complete regression of angle and scleral NV at 2-7 d postoperatively of the experimental group was 94.00%,which was obviously higher than 80.00% of the control group,and the difference was statistically significant(P<0.05).After 7 d and 1 month of treatment,the intraocular pressures in the experimental group were(21.18±4.57) and(22.06±4.61) mm Hg(1 mm Hg=0.133 kPa),which were significantly lower than(24.06±5.03) and(25.07±5.13) mm Hg in the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,there was no statistically significant difference in intraocular pressure between the two groups(P>0.05).The differences were not statistically significant when comparing the incidence of vesicle formation,gravitational tube blockage or displacement exposure,iridocyclitis,anterior chamber hemorrhage,superficial anterior chamber,and hypotony between the two groups(P>0.05).Conclusion The short-term effect of ranibizumab is better than that of conbercept in the treatment of neovascular glaucoma.The long-term effect of the two treatment methods is not obvious,and the two treatment methods have less adverse reactions and high safety,which is worthy of clinical promotion and application.

关 键 词：康柏西普 雷珠单抗 新生血管性青光眼 临床疗效 

分 类 号：R775[医药卫生—眼科]